Abeona Therapeutics Inc (NASDAQ:ABEO – Get Free Report) SVP Brendan M. O’malley acquired 3,000 shares of the firm’s stock in a transaction that occurred on Monday, September 18th. The shares were purchased at an average price of $3.80 per share, with a total value of $11,400.00. Following the acquisition, the senior vice president now owns 187,421 shares of the company’s stock, valued at approximately $712,199.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Abeona Therapeutics Price Performance
NASDAQ ABEO traded up $0.05 during trading hours on Tuesday, reaching $3.72. 17,486 shares of the company’s stock were exchanged, compared to its average volume of 163,779. The company’s 50-day moving average is $3.74 and its two-hundred day moving average is $3.49. Abeona Therapeutics Inc has a one year low of $2.19 and a one year high of $5.80.
Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.66) by $0.22. The company had revenue of $3.50 million for the quarter. Analysts anticipate that Abeona Therapeutics Inc will post -1.99 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Institutional Trading of Abeona Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of the company. Goldman Sachs Group Inc. boosted its position in shares of Abeona Therapeutics by 30.6% during the second quarter. Goldman Sachs Group Inc. now owns 213,282 shares of the biopharmaceutical company’s stock worth $860,000 after buying an additional 50,008 shares during the period. State Street Corp boosted its position in Abeona Therapeutics by 18.0% during the 2nd quarter. State Street Corp now owns 51,095 shares of the biopharmaceutical company’s stock worth $206,000 after acquiring an additional 7,800 shares during the last quarter. BlackRock Inc. grew its stake in shares of Abeona Therapeutics by 156.2% during the 2nd quarter. BlackRock Inc. now owns 142,785 shares of the biopharmaceutical company’s stock worth $575,000 after acquiring an additional 87,057 shares in the last quarter. Northern Trust Corp raised its holdings in shares of Abeona Therapeutics by 206.4% in the second quarter. Northern Trust Corp now owns 103,235 shares of the biopharmaceutical company’s stock valued at $416,000 after purchasing an additional 69,539 shares during the last quarter. Finally, Citigroup Inc. acquired a new stake in shares of Abeona Therapeutics in the second quarter valued at approximately $806,000. Institutional investors and hedge funds own 43.97% of the company’s stock.
About Abeona Therapeutics
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
- Five stocks we like better than Abeona Therapeutics
- What is the NASDAQ Stock Exchange?
- 2 Beauty Stocks Beaten By the Ugly Stick But Ready to Rally
- Dividend Capture Strategy: What You Need to Know
- Got Nuclear? Three Stocks To Play Energy’s Next Frontier
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- The Top 4 Utilities for Value, Yield, and Upside Potential
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.